Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Mirum Pharmaceuticals Inc. stock reached an all-time high of 72.28 USD, marking a significant milestone for the company. The stock’s impressive momentum is reflected in its financial health metrics, with InvestingPro data showing a robust current ratio of 3.13 and substantial revenue growth of 62.33% in the last twelve months. Over the past year, the stock has experienced a remarkable increase of 62.28%, reflecting strong investor confidence and positive market sentiment. This surge in stock price highlights the company’s growth trajectory and potential in the pharmaceutical industry. According to InvestingPro analysis, the stock appears overvalued at current levels, with technical indicators suggesting overbought conditions. Investors are closely watching Mirum Pharmaceuticals as it continues to capitalize on its recent successes and strategic initiatives. For deeper insights, discover 15 additional ProTips and comprehensive analysis in the Pro Research Report.
In other recent news, Mirum Pharmaceuticals reported strong financial results for the second quarter of 2025, with total revenues reaching $127.8 million. This marks a 64% year-over-year growth compared to $77.9 million in the same period of 2024. The company’s earnings per share (EPS) stood at -$0.12, significantly beating the forecasted -$0.33. Mirum’s management has raised its 2025 guidance to $490 million to $510 million, indicating a 48% year-over-year growth at the midpoint. Following these results, JMP Securities increased its price target for Mirum Pharmaceuticals to $81, maintaining a Market Outperform rating. Similarly, H.C. Wainwright raised its price target to $80 while maintaining a Buy rating. Stifel also resumed coverage of Mirum Pharmaceuticals with a Buy rating, highlighting the company’s cash-flow positive, high-growth commercial business. These developments reflect positively on Mirum’s financial trajectory and potential future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.